PCSA · Processa Pharmaceuticals, Inc.

Substantial doubt about the company's ability to continue as a going concern.

“Absent additional funding, we believe that our cash and cash equivalents, along with our digital assets, will not be sufficient to fund our operations for a period of one year or more after the date that these consolidated financial statements are available to be issued based on the timing and amount of our projected net loss from continuing operations and cash to be used in operating activities during that period of time. As a result, substantial doubt exists about our ability to continue as a going concern within one year after the date that these consolidated financial statements are available to be issued.”